NuCana PLC
NASDAQ:NCNA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NuCana PLC
Accounts Payable
NuCana PLC
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NuCana PLC
NASDAQ:NCNA
|
Accounts Payable
£522k
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Accounts Payable
$9.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Accounts Payable
£24.4m
|
CAGR 3-Years
28%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Accounts Payable
$15.2m
|
CAGR 3-Years
47%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Accounts Payable
£19.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-9%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Accounts Payable
£49.6m
|
CAGR 3-Years
54%
|
CAGR 5-Years
45%
|
CAGR 10-Years
30%
|
|
NuCana PLC
Glance View
NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. The firm is focused on developing treatments for cancer patients using its ProTide technology. ProTide are designed to overcome cancer resistance mechanism and generate anti-cancer metabolites in cancer cells. The firm's pipeline includes Acelari, NUC-3373, and NUC-7738. Its ProTide candidates Acelari and NUC-3373 are chemical entities derived from the nucleotide analog and 5- fluorouracil, which are used as chemotherapy agents for the treatment of cancer. Acelari is in a Phase III study for patients with biliary tract cancer. NUC-3373 is in Phase I study for the treatment of a range of patients with solid tumors and a Phase I b study for patient with metastatic colorectal cancer. Its third ProTide candidate, NUC-7738, is a nucleotide analog (3’-deoxyadenosine) and is in Phase I study for patients with solid tumors.
See Also
What is NuCana PLC's Accounts Payable?
Accounts Payable
522k
GBP
Based on the financial report for Dec 31, 2025, NuCana PLC's Accounts Payable amounts to 522k GBP.
What is NuCana PLC's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
-25%
Over the last year, the Accounts Payable growth was -81%. The average annual Accounts Payable growth rates for NuCana PLC have been -52% over the past three years , -25% over the past five years .
